Enrico Jose Adolfo Bastianelli

Procter & Gamble Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its products include Actonel, Asacol, Enablex, Didronel, Macrobid, Macrodantin, Entex, and Ziac. The firm manufactures and markets a variety of over-the-counter and oral care products such as Crest, Oral-B, Prilosec OTC, Vicks, Metamucil, Pepto-Bismol, ThermaCare, and other related products. The company was founded in 1970 and is headquartered in Cincinnati, OH.

Part of Université Libre de Bruxelles, Hôpital Erasme is a medical facility located in Brussels, Belgium. The hospital offers polyclinics in Nivelles and Brussels, as well as specialized centers in psychiatry, geriatrics, and traumatology.

Bone Therapeutics SA is a cell therapy company, which engages in the regenerative therapy addressing for unmet medical needs in the field of bone diseases and orthopedics. Its products include Allob and JTA-004. The company was founded by Jacques Reymann on June 16, 2006 and is headquartered in Gosselies, Belgium.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Pepric NV develops imaging technology. It offers sensitive imaging systems with a long observation window for in-vivo molecular and functional imaging addressing pharmaceutical applications in drug development, pre-clinical testing, diagnostic imaging and translational medicine in general. The company was founded Stephanie Laura Gerard Claire Teughels in 2009 and is headquartered in Leuven, Belgium.

Apaxen SA is a privately-held biotechnology company that was founded in 2018 and is based in an undisclosed location. The Belgian company has raised €5.4 million in equity and grant funding since its A round in 2019. Apaxen is focused on developing a pipeline of NLRP3 inflammasome inhibitors with a novel mechanism of action for the treatment of chronic inflammatory and autoimmune diseases. The company's clinical candidate, MFC-1040, is an orally bioavailable and selective small molecule NLRP3 inflammasome inhibitor that has demonstrated efficacy in multiple animal models of chronic inflammatory disease and pulmonary fibrosis. The company's team combines the experience required for clinical development of its products and is supported by a world-class team of scientific advisors. Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 inflammasome activation. The company was founded in 2018 by Gael Jalce, Enrico Jose Adolfo Bastianelli, and Bart Wuurman has been the CEO of the company since 2020.

Graftys SA designs, manufactures and markets calcium phosphate-based synthetic bone substitutes to the global orthopedic and dental surgery markets. Its research and development projects include injectable and resorbable synthetic bone substitutes, biological repair of cartilage and of the spine, as well as bone substitutes combined with pharmaceutical agents. The company was founded by Jean Marc Ferrier, Alain Valet, Jean-Michel Bouler and Aurélien Valet in September 2005 and is headquartered in Aix-en-Provence, France.